Correction to: Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome

Correction to : Pediatr Nephrol (2022) 37:37–47

https://doi.org/10.1007/s00467-021–04985-1

The original version of this article unfortunately contained a mistake. In the fifth paragraph of the section entitled “Is there a future for corticosteroids in the treatment of steroid-sensitive nephrotic syndrome?”, they refer to a study that used a non-corticosteroid drug as part of initial regimen. That drug should be azithromycin not azathioprine as they noted. The corrected paragraph is presented below. The authors apologize for this mistake. The original article has been corrected.

All these trials only consider children who have entered remission on conventional high-dose corticosteroids and, as yet, there is only one published trial where non-corticosteroids are used as part of the induction regimen, showing some benefit of 3 days of azithromycin with the initial corticosteroid course [123]. In adult minimal change disease, a French study of considerable interest to pediatric nephrologists has recently opened, which will evaluate rituximab used at initial presentation (NCT03970577). As yet, there are no published or current trials of non-corticosteroid treatments without corticosteroids and it looks as though the presence of corticosteroids in the treatment of nephrotic syndrome will remain for many years yet.

123. Zhang B, Liu T, Wang W, Zhang X, Fan S, Liu Z, Liu Z, Wu X (2014) A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome. Eur J Pediatr 173:509–515.